uniQure shares tumble as Huntington’s gene therapy shows weaker four-year cUHDRS benefit

uniQure has delivered the kind of clinical update that can sharply divide regulators and investors, with new four-year Huntington’s disease data showing continued functional benefit from ifezuntirgene inilparvovec but a substantially weaker result on a key disease-progression measure than investors saw at three years. High-dose patients experienced an estimated 44% slowing on the composite Unified Huntington’s Disease Rating Scale compared with an external control, but the difference did not reach statistical significance, while Total Functional Capacity showed a statistically stronger 61% slowing. The mixed durability picture triggered a severe market reaction, with uniQure shares falling more than 35% during the session after trading above $39 previously. The selloff raises the stakes around a Biologics License Application that has already been submitted to the FDA using the more favorable three-year dataset rather than the newly reported four-year results.

That distinction is crucial to the investment case. The FDA previously agreed that uniQure’s three-year Phase I/II data could provide a reasonable basis for an accelerated-approval filing, and the company formally submitted that application earlier this month while requesting Priority Review. The four-year update does not replace the dataset supporting the BLA, but regulators are unlikely to ignore newer evidence showing that the apparent effect on one major endpoint weakened as follow-up lengthened.

Four-year results preserve a functional benefit but weaken the headline efficacy narrative

The high-dose four-year analysis included 12 patients who received a single administration of ifezuntirgene inilparvovec, previously known as AMT-130. Their outcomes were compared with propensity score-matched patients from the ENROLL-HD natural-history database, allowing uniQure to estimate how rapidly treated patients progressed relative to a clinically similar untreated population.

On the composite Unified Huntington’s Disease Rating Scale, high-dose patients declined by an average of 0.90 points compared with 1.61 points in the external control. That represented an estimated 44% slowing of progression, but the nominal p-value of 0.144 meant the result did not meet the conventional threshold for statistical significance.

That figure contrasts with the stronger three-year picture that drove enthusiasm around the program. In the newly expanded 36-month analysis of 15 high-dose patients, cUHDRS decline was slowed by an estimated 80% compared with matched natural-history controls, with a nominal p-value of 0.005. Total Functional Capacity showed an estimated 67% slowing at three years.

The four-year Total Functional Capacity result remained more encouraging. High-dose patients declined by an average of 0.37 points compared with 0.94 points in the external control, producing an estimated 61% slowing and a nominal p-value of 0.008. Because TFC measures practical abilities such as work, household responsibilities and self-care, preservation on this scale could carry meaningful clinical relevance if the effect proves durable.

For investors, however, the divergence between the endpoints complicates the narrative. The therapy still appears to separate from untreated disease on several measures, but the four-year data are no longer as straightforward as the three-year results that supported the regulatory filing.

Missing external-control data create another layer of uncertainty for the FDA review

The external-control methodology has always been central to uniQure’s regulatory strategy because the Phase I/II program does not include a conventional long-term randomized untreated control arm. Instead, treated patients are matched with individuals from ENROLL-HD, a large Huntington’s disease natural-history database.

That approach became more difficult to interpret at four years because approximately 53% of relevant observations were missing in the updated external-control dataset. uniQure said patients who disappeared from follow-up appeared to have been progressing more rapidly before their data were lost, potentially leaving a healthier group of control patients at the later time point.

If that explanation is correct, the remaining external controls could make Huntington’s disease appear to progress more slowly than it ordinarily would, reducing the measured difference between treated and untreated patients. uniQure conducted a post hoc sensitivity analysis using an earlier version of the external-control dataset and reported stronger four-year results under that comparison.

The methodological issue still creates regulatory uncertainty. Post hoc analyses generally carry less evidentiary weight than prespecified comparisons, and the FDA will have to determine whether the natural-history control remains sufficiently reliable as follow-up extends.

This question matters because the company is pursuing accelerated approval without a large randomized pivotal trial completed before submission. The FDA has already signaled that a confirmatory study will be required and previously discussed a randomized standard-of-care control design that would need to be underway around the time of any accelerated approval.

The agency therefore has several layers of evidence to consider: a statistically strong three-year analysis, supportive but mixed four-year data, substantial missingness in the external comparator and an ongoing need for prospective confirmation.

Submitted BLA makes regulatory interpretation more important than the immediate stock reaction

uniQure submitted its BLA seeking accelerated approval for ifezuntirgene inilparvovec after receiving feedback from the FDA that filing on the existing clinical dataset was reasonable. The company also requested Priority Review, which could shorten the FDA review cycle to six months after the agency completes its initial filing review.

The application is based primarily on the three-year high-dose analysis rather than the newly released four-year dataset. That gives uniQure an important regulatory argument: the evidence originally discussed with the FDA has actually strengthened at 36 months as three additional high-dose patients reached that follow-up point.

The expanded three-year dataset now includes 15 high-dose patients and shows an estimated 80% slowing on cUHDRS and 67% slowing on Total Functional Capacity. Those results are stronger than the dataset available when uniQure initially discussed the accelerated-approval pathway with regulators.

The risk is that a regulator evaluating durability may still consider what happens beyond the primary filing time point. A four-year result showing continued separation but a smaller and statistically non-significant cUHDRS difference could prompt additional questions around the magnitude, persistence and reliability of treatment benefit.

That does not automatically mean rejection. Huntington’s disease has no approved therapy proven to slow underlying disease progression, creating substantial unmet medical need, and the four-year TFC result remains supportive. The FDA must weigh those factors alongside uncertainty arising from sample size, external controls and the invasive nature of treatment.

uniQure’s stock collapse shows how much valuation had become tied to AMT-130 durability

The market reaction illustrates how heavily uniQure’s valuation depends on ifezuntirgene. Shares had closed the previous session at $39.11 after trading above $50 earlier in the month, but fell more than 35% following the four-year release. Premarket losses had briefly exceeded 60% before some of the decline narrowed after trading opened.

Investors appear to have focused primarily on the drop from the strong three-year cUHDRS effect to the weaker four-year comparison. The non-significant p-value also matters because uniQure had increasingly been valued as a company approaching potential commercialization rather than simply another early-stage gene therapy developer.

Before the update, uniQure carried a market capitalization of roughly $2.7 billion based on its previous closing price. A decline of more than one-third therefore removes a substantial amount of equity value in a single session even though the BLA remains under FDA consideration.

Some analysts remained more constructive after reviewing the full dataset, pointing to the statistically stronger TFC outcome, continued dose-response pattern and the fact that the regulatory filing relies on three-year rather than four-year data. Those views do not remove regulatory risk, but they help explain why the shares recovered from their extreme premarket decline.

The market now appears to be assigning a larger discount to approval probability and commercial durability. Until the FDA clarifies whether it accepts the BLA for filing and how it views the four-year data, that uncertainty is likely to remain central to uniQure’s valuation.

Stronger balance sheet gives uniQure resources to prepare for launch and confirmatory testing

The company entered this regulatory period with a much stronger balance sheet than it held previously. uniQure completed a $259 million follow-on financing that extended its expected cash runway into 2030 and said the additional capital should support a potential commercial launch of ifezuntirgene as well as continued development across the rest of its pipeline.

That financing reduces one immediate risk created by the stock decline. uniQure does not need to return quickly to the equity markets simply to maintain the Huntington’s program, giving management flexibility while the FDA reviews the application and while the company prepares the confirmatory study required under an accelerated-approval strategy.

The balance sheet could also support the specialized commercial infrastructure required for a gene therapy delivered through MRI-guided stereotactic neurosurgery. Unlike a conventional prescription medicine, ifezuntirgene would require trained treatment centers, neurosurgical capacity and coordinated patient referral pathways.

Those requirements may limit how quickly the product could penetrate the market even if approved. They could also support premium pricing if the therapy demonstrates durable disease modification after one administration, although uniQure has not disclosed a commercial price.

The addressable population remains meaningful for a rare-disease gene therapy. Approximately 75,000 people across the United States, European Union and United Kingdom are estimated to have Huntington’s disease, with many more genetically at risk. There remains no approved treatment demonstrated to slow the underlying progression of the condition.

FDA acceptance and Priority Review now become the next major catalysts for uniQure

The four-year results do not settle the ifezuntirgene investment case. Instead, they shift attention even more heavily toward regulatory interpretation. A successful FDA filing acceptance would confirm that regulators consider the submitted package sufficiently complete for substantive review, while a Priority Review designation would establish a shorter decision timeline. The company’s confirmatory trial design will also become important because accelerated approval would require uniQure to verify clinical benefit after commercialization.

The updated three-year evidence gives uniQure a stronger version of the dataset originally discussed with the FDA, while four-year Total Functional Capacity continues to show meaningful separation. At the same time, the weaker cUHDRS result, small patient numbers and increasing missingness in the natural-history comparator create genuine uncertainty that cannot be dismissed as a short-term market overreaction.

That tension explains the magnitude of the stock decline. Investors had increasingly priced ifezuntirgene as a potentially approvable disease-modifying Huntington’s therapy, making any evidence suggesting that the treatment effect may weaken over time especially consequential.

The next stage will therefore depend less on another percentage comparison and more on how the FDA interprets the entire body of evidence. If regulators remain comfortable with the three-year external-control analysis and require prospective confirmation after accelerated approval, uniQure could still move toward the first disease-modifying Huntington’s treatment. If the four-year durability questions materially change that assessment, the company may face a much longer and more expensive path to market.

Key takeaways from uniQure’s four-year Huntington’s data and FDA review

• Four-year high-dose data showed a 44% slowing on cUHDRS, but the comparison was not statistically significant.
• Total Functional Capacity remained stronger, showing an estimated 61% slowing of decline at four years.
• Expanded three-year data showed an 80% slowing on cUHDRS and 67% on TFC, both statistically stronger results.
• uniQure’s submitted BLA is based primarily on the three-year dataset rather than the new four-year analysis.
• Missing data reached about 53% in the four-year external-control population, complicating interpretation of durability.
• The FDA previously agreed that filing for accelerated approval using the existing Phase I/II evidence was reasonable.
• uniQure shares fell more than 35% as investors reacted to the weaker four-year cUHDRS result.
• A $259 million financing has extended uniQure’s expected cash runway into 2030 and supports potential launch preparations.
• FDA filing acceptance, possible Priority Review and the confirmatory trial design are now the program’s most important catalysts.